The Randomized Controlled Trial of Inferior Vena Cava Ultrasound-guided Fluid Management in Septic Shock Resuscitation

• Status: Completed
• Trial end date: 2020-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The primary aim of this study is to evaluate the 30-day mortality outcome of the septic shock patients who are treated with ultrasound-assisted fluid management using change of the inferior vene cava (IVC) diameter during respiratory phases in the first 6 hours compared with those treated with "usual-care" strategy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chulalongkorn University
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Dopamine; Epinephrine; Norepinephrine; Vasoconstrictor Agents

Criteria

Inclusion Criteria:

• Patient who attended the emergency department with septic shock (defined by those who require a vasopressor to maintain a mean arterial pressure (MAP) of 65 mm Hg or greater and whose serum lactate level greater than 2 mmol/L in the absence of hypovolemia.)

Exclusion Criteria:

• 1) Congestive pulmonary edema or known to have poor systolic cardiac function (left ventricular ejection fraction ≤ 40%).

• 2) Known to have right heart pathologies.

• 3) Having or suspected to have marked ascites, significant bowel dilatation or the conditions that can cause abdominal hypertension.

• 4) Body mass index ≥ 30 kg/square meter.

• 5) Having concomitant attack of severe airway disease (eg. Asthma, COPD) that may have confounded the IVC interpretation due to the positive intrathoracic pressure.

• 6) IVC can not be identified or its diameter cannot be measured correctly.

• 7) Having end-stage renal diseases with or without dialysis.

• 8) Having non-infectious diseases as final diagnoses.

• 9) Pregnant women.

• 10) Have been referred or treated from other healthcare facility.

• 11) Having active hemorrhages.

• 12) Duplicated cases.

• 13) who had "do-not-resuscitate" living will.

• 14) Declined to consent.